<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04313790</url>
  </required_header>
  <id_info>
    <org_study_id>IVSCHEP</org_study_id>
    <nct_id>NCT04313790</nct_id>
  </id_info>
  <brief_title>Assessment of Pleotropic Effect of Heparin Infusion Versus Subcutaneous Injection in Septic Shock Patients</brief_title>
  <official_title>Assessment of Thrombo-prophylactic and Anti Inflammatory Effect of Unfractionated Heparin by Intravenous Infusion Versus Subcutaneous Injection in Critically Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Venous thromboembolism (VTE), including pulmonary embolism (PE) and deep venous thrombosis
      (DVT), is a common and severe complication of critical illness. Critically ill patients are
      at high risk of VTE because they combine both general risk factors together with specific ICU
      risk factors of VTE.Vasopressor administration was found to be an independent risk factor for
      DVT. certainly explained by reduced absorption of subcutaneous heparin linked to the
      vasoconstriction of peripheral blood vessels. Critically ill patients, due to altered
      pharmacokinetics behavior of unfractionated heparin, continuous intravenous infusion of the
      low doses of unfractionated heparin has been proposed. Standard prophylaxis with subcutaneous
      (SC) heparin is less efficient in patients requiring vasopressors .Sepsis is a systemic
      inflammatory response due to an infection. Both inflammatory mediators and coagulation are
      involved in sepsis. the release of the inflammatory mediators such as interleukins and tumor
      necrosis factor cause damage of the endothelium and activation of coagulation which promotes
      inflammatory process .Unfractionated heparin is the most negatively charged biological
      molecule known, heparin has a strong ability to interfere with the functioning of positively
      charged molecules. Due to the difference in charges, heparin has been documented to interact
      with over 100 proteins.57 Interleukins, cytokines, and receptors located on endothelial
      cells, which are involved in the acute phase response, are positively charged, and thus are a
      reasonable target for the modulating effects of heparin. Heparin has strong anti-inflammatory
      effects with many possible mechanisms, including binding to cell-surface glycosaminoglycan's,
      preventing leukocyte migration, direct binding to chemokines and cytokines, and inhibition of
      intracellular NF-kB .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Ethical committee approval will be obtained from Ethics committee of Faculty of
           Pharmacy, Damanhour University.

        2. All participants or their next kin should agree to participate in this clinical study
           and will provide informed consent.

        3. 100 participants who are critically ill with septic shock.

        4. The 100 participants will be randomly assigned into 2 groups:

             -  Standard care group: will be treated with subcutaneous heparin 5000 units three
                times daily for DVT prophylaxis.

             -  Experimental group: will be treated with heparin infusion 5000 unit\hour for DVT
                prophylaxis

        5. All patients will be subjected directly at time of enrollment to the following:

             -  Full patient history and clinical examination.

             -  complete blood picture, liver function tests, renal function tests.

             -  The initial cause of ICU admission and define the origin of present infection.

             -  Complete cultures obtained urine, blood and sputum.

             -  Coagulation profile (prothrombin time, prothrombin activity, international
                normalization ratio (INR), clotting time and activated partial thromboplastin
                time).

             -  Arterial blood gases analysis (including hypoxic index).

             -  The severity of disease assessment using Acute Physiology and Chronic Health
                Evaluation version II (APACHE II) score.

             -  Organ failure assessment using Organ Failure Assessment (SOFA) score and quick
                (SOFA) score.

             -  Kidney assessment using Kidney Disease Improving Global Outcomes (KDIGO) criteria.

             -  Liver disease assessment using Child Pugh Score.

             -  Chest radiography, electrocardiography and transthoracic echocardiography.

             -  Vital signs (systolic blood pressure, diastolic blood pressure, heart rate,
                respiratory rate temperature, blood sugar level and urine output).

        6. All patients will be monitored for the incidence of DVT, minor and major bleeding during
           their intensive care unit stay (ICU).

        7. Coagulation profile, serum lactate, serum electrolytes, hypoxic index,28-day mortality
           and the following pro inflammatory biomarkers will be measured at the start and at day 2
           of the study.

           i. CRP ii. Heparin binding protein (HBP) iii. IL-6 iv. Neutrophil gelatinase -associated
           lipocalin (NGAL). v. Plasminogen activator inhibitor (PAI).

        8. Patients demographic data will be recorded with respect to sex. age, weight, disease and
           medication history.

        9. Statistical tests appropriate to the study design will be conducted to evaluate the
           significance of the results.

       10. Results, conclusion, discussion and recommendations will be given.

       11. A P value of less than 0.05 will be considered statistically significance.

       12. Statistical analysis will be performed by STATA/IC (version 16 for Windows); Stata Corp
           LP, College Station, TX.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 24, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized Control Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>double(Participant,Care provider)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thrombo-embolism</measure>
    <time_frame>14 days</time_frame>
    <description>Any occurrence of thromboembolism event</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hypoxic index</measure>
    <time_frame>7 days</time_frame>
    <description>Arterial blood gases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole blood clotting time</measure>
    <time_frame>7 days</time_frame>
    <description>bedside clotting time measurement</description>
  </primary_outcome>
  <primary_outcome>
    <measure>28-days mortality</measure>
    <time_frame>28 days</time_frame>
    <description>All causes of mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lactic acid</measure>
    <time_frame>5 days</time_frame>
    <description>serum lactate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressor use</measure>
    <time_frame>5 days</time_frame>
    <description>Duration and dose of circulatory support</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated partial prothrombin time</measure>
    <time_frame>7 days</time_frame>
    <description>measurement changes of activated partial prothrombin time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heparin binding protein</measure>
    <time_frame>8 hours</time_frame>
    <description>plasma level of HBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen activator inhibitor (PAI)</measure>
    <time_frame>2 days</time_frame>
    <description>serum level of PAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil gelatinase -associated lipocalin (NGAL).</measure>
    <time_frame>7 days</time_frame>
    <description>plasma NGAL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>7 days</time_frame>
    <description>plasma CRP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Septic Shock</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Heparin Infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>heparin infusion 500unit \hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneus Heparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>subcutaneous heparin 5000unit \ 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin Infusion</intervention_name>
    <description>500 unit heparin infusion \ hour for DVT prophylaxis experimental group (n=50)</description>
    <arm_group_label>Heparin Infusion</arm_group_label>
    <other_name>new regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>subcutaneous heparin</intervention_name>
    <description>5000 unit subcutaneous heparin /8 hours control group n=(50)</description>
    <arm_group_label>Subcutaneus Heparin</arm_group_label>
    <other_name>conventional regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults Patients aged 18 years old or greater diagnosed with septic shock. The
             diagnosis of sepsis was made according to &quot;surviving sepsis campaign: international
             guidelines for management of severe sepsis and septic shock&quot; by Sepsis-3 task force
             defines sepsis as the presence of suspected infection along with rise in total SOFA
             score ≥2 from baseline.

        Exclusion Criteria:

          -  Need for corticosteroids

          -  vasopressors likely to be discontinued in the next 6 hours

          -  Received vasopressor therapy for greater than 18 hours prior to enrolment.

          -  Pregnancy

          -  High risk for bleeding

          -  Requirement of therapeutic anticoagulant

          -  PLT &lt; 50_106 per mL

          -  History of HIT

          -  Allergy to heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Salahuddin, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aymen A Eltayar, MD</last_name>
    <role>Study Director</role>
    <affiliation>Damanhour Teatching Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noha A Bassiony, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amira B Kassem, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Damanhour University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nouran A Elsheikh, pharm-D</last_name>
    <phone>01229001312</phone>
    <phone_ext>01090602858</phone_ext>
    <email>nouranelsheikh@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amira B Kassem, PHD</last_name>
    <phone>01222960523</phone>
    <email>amirabisher@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Cook D, Crowther M, Meade M, Rabbat C, Griffith L, Schiff D, Geerts W, Guyatt G. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med. 2005 Jul;33(7):1565-71.</citation>
    <PMID>16003063</PMID>
  </reference>
  <reference>
    <citation>Dörffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Büller HR, Levi M. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet. 2002 Mar 9;359(9309):849-50.</citation>
    <PMID>11897286</PMID>
  </reference>
  <reference>
    <citation>Selby R, Geerts W. Prevention of venous thromboembolism: consensus, controversies, and challenges. Hematology Am Soc Hematol Educ Program. 2009:286-92. doi: 10.1182/asheducation-2009.1.286. Review.</citation>
    <PMID>20008212</PMID>
  </reference>
  <reference>
    <citation>Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S.</citation>
    <PMID>15383472</PMID>
  </reference>
  <reference>
    <citation>Jaimes F, De La Rosa G, Morales C, Fortich F, Arango C, Aguirre D, Muñoz A. Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study). Crit Care Med. 2009 Apr;37(4):1185-96. doi: 10.1097/CCM.0b013e31819c06bc.</citation>
    <PMID>19242322</PMID>
  </reference>
  <reference>
    <citation>Wang C, Chi C, Guo L, Wang X, Guo L, Sun J, Sun B, Liu S, Chang X, Li E. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Crit Care. 2014 Oct 16;18(5):563. doi: 10.1186/s13054-014-0563-4. Review.</citation>
    <PMID>25318353</PMID>
  </reference>
  <reference>
    <citation>Lorente L, Martín MM, Borreguero-León JM, Solé-Violán J, Ferreres J, Labarta L, Díaz C, Jiménez A, Páramo JA. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients. Thromb Res. 2014 Jul;134(1):182-6. doi: 10.1016/j.thromres.2014.04.013. Epub 2014 Apr 29.</citation>
    <PMID>24814968</PMID>
  </reference>
  <reference>
    <citation>Elsayed E, Becker RC. The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J Thromb Thrombolysis. 2003 Feb;15(1):11-8. Review.</citation>
    <PMID>14574071</PMID>
  </reference>
  <reference>
    <citation>Li L, Pian Y, Chen S, Hao H, Zheng Y, Zhu L, Xu B, Liu K, Li M, Jiang H, Jiang Y. Phenol-soluble modulin α4 mediates Staphylococcus aureus-associated vascular leakage by stimulating heparin-binding protein release from neutrophils. Sci Rep. 2016 Jul 7;6:29373. doi: 10.1038/srep29373.</citation>
    <PMID>27383625</PMID>
  </reference>
  <reference>
    <citation>Chen S, Xie W, Wu K, Li P, Ren Z, Li L, Yuan Y, Zhang C, Zheng Y, Lv Q, Jiang H, Jiang Y. Suilysin Stimulates the Release of Heparin Binding Protein from Neutrophils and Increases Vascular Permeability in Mice. Front Microbiol. 2016 Aug 26;7:1338. doi: 10.3389/fmicb.2016.01338. eCollection 2016.</citation>
    <PMID>27617009</PMID>
  </reference>
  <reference>
    <citation>Tydén J, Herwald H, Hultin M, Walldén J, Johansson J. Heparin-binding protein as a biomarker of acute kidney injury in critical illness. Acta Anaesthesiol Scand. 2017 Aug;61(7):797-803. doi: 10.1111/aas.12913. Epub 2017 Jun 5.</citation>
    <PMID>28585315</PMID>
  </reference>
  <reference>
    <citation>Fisher J, Russell JA, Bentzer P, Parsons D, Secchia S, Mörgelin M, Walley KR, Boyd JH, Linder A. Heparin-Binding Protein (HBP): A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury. Shock. 2017 Sep;48(3):313-320. doi: 10.1097/SHK.0000000000000862.</citation>
    <PMID>28319494</PMID>
  </reference>
  <reference>
    <citation>Lin Q, Shen J, Shen L, Zhang Z, Fu F. Increased plasma levels of heparin-binding protein in patients with acute respiratory distress syndrome. Crit Care. 2013 Jul 24;17(4):R155. doi: 10.1186/cc12834.</citation>
    <PMID>23883488</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 9, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2020</study_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heparin infusion</keyword>
  <keyword>DVT prophylaxis</keyword>
  <keyword>Anti inflammatory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

